Sukesh Sukumaran
University of Arkansas for Medical Sciences
USA
Title: Symposium on Dermatological manifestations in pediatric rheumatology patients- the era of new biological medications
Biography
Biography: Sukesh Sukumaran
Abstract
Rheumatic diseases have a wide variety of cutaneous manifestations especially in the pediatric population. The dermatologic manifestations may be the sole features in some of the rheumatic diseases especially at the initial presentation. The common rheumatic diseases include the pediatric systemic lupus erythematosus, juvenile dermatomyositis, systemic onset juvenile idiopathic arthritis, juvenile scleroderma and juvenile psoriasis. Dermatological manifestations are also seen with less common rheumatic diseases including the periodic fever syndrome, SAPHO syndromes, Neutrophilic dermatoses and pediatric vasculitis. The timely recognition of these rashes helps to diagnose the underlying rheumatic disease and also to start appropriate immune modulation. With the new biological management of the rheumatic disease the challenges are higher as initiation of the appropriate treatment within the therapeutic window will help to alleviate the long term damage to the joints or internal organs. The biologics commonly used in pediatric rheumatology includes different anti TNF agents (etanercept, adalimumab, infliximab), anti IL1 (anakinra, canakinumab, rilanocept), anti IL6- tocilizumab, anti B cell treatment with rituximab and belimumab, co stimulatory inhibitors like abatacept, anti IL12/23 agent and IL17 agent like secukinumab. The medications used to treat different rheumatic conditions lead to dermatological manifestations and implicated in the new onset of cutaneous lupus and drug induced lupus. The topic is very important as the field of rheumatology and dermatology is changing its face every day with the advent of new biologic medications. In this talk we are focusing on the rheumatic diseases with cutaneous manifestations and new biologic medications.